TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

62 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • COPD (chronic lung disease)

    A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

    Testing two doses of a medicine versus placebo for COPD symptoms

    📍 Research Site · Birmingham, AL · +39 more US sites · Get directions →

    This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.

    ✓ Study care freePhase 2Ages 40+Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

    Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson

    📍 Domino's Farms · Ann Arbor, MI · Get directions →

    The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.

    ✓ Study care freePhase 1Ages 45+Learn more →
  • Parkinson's disease

    Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

    Testing a non-invasive brain stimulation device to improve Parkinson’s movement problems

    📍 U LLC Headquarters · Cleveland, OH · Get directions →

    This study tests a new, non-invasive brain stimulation device called Sphere V3.0 to help improve movement problems in people with Parkinson's disease. The device delivers gentle electrical signals to the scalp using small electrodes placed on the head.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +1 more US site · Get directions →

    This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B).

    ✓ Study care freePhase 1Ages 18–65Learn more →
  • Parkinson's disease

    Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

    Testing whether a low-dose seizure medicine can help Parkinson’s psychosis

    📍 Johns Hopkins · Baltimore, MD · Get directions →

    This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Parkinson's disease

    A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    Testing a treatment in people with early Parkinson’s disease who have an LRRK2 gene test result

    📍 Banner Sun Health Research Institute · Sun City, AZ · +39 more US sites · Get directions →

    The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    A Study of Buntanetap in Participants With PD

    Testing the long-term safety of buntanetap in people with Parkinson’s

    📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →

    This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →

    The primary objective of this trial is to evaluate the dose-dependent and comparative effects of ECC4703 (low and high dose), ECC0509 (low and high dose), and their combination on hepatic fat reduction as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 12.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • COPD (chronic lung disease)

    To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

    Testing two doses of a daily medicine versus placebo in people with COPD over 52 weeks

    📍 DM Clinical Research - Phoenix · Phoenix, AZ · +11 more US sites · Get directions →

    This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Fatty liver disease (NASH/MASH)

    Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)

    Testing whether daily soy milk affects liver disease in children with fatty liver

    📍 Cincinnati Children's Hospital Medical Center · Cincinnati, OH · Get directions →

    A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities.

    ✓ Study care freePhase 2Ages 5–12Learn more →
  • Fatty liver disease (NASH/MASH)

    Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)

    Testing how the liver responds to glucose in fatty liver disease, and semaglutide’s effect

    💵 May compensate

    📍 National Institutes of Health Clinical Center · Bethesda, MD · Get directions →

    Background: In non-alcoholic fatty liver disease (NAFLD), fat accumulates in the liver and can cause damage. Researchers want to learn what causes the damage NAFLD, and to see if a medication can help.

    ✓ Study care freePhase 2Ages 18–100Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health - Chandler · Chandler, AZ · +30 more US sites · Get directions →

    Rivus Pharmaceuticals. Inc. is sponsoring this research study to assess the safety and tolerability of HU6 as a possible treatment for patients diagnosed with metabolic dysfunction-associated steatohepatitis (MASH). The study will also asse

    ✓ Study care freePhase 2Ages 30+Learn more →
  • Fatty liver disease (NASH/MASH)

    Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease

    Testing how SGLT2 inhibitors work for fatty liver disease in obese teens

    💵 May compensate

    📍 Ann & Robert H Lurie Children's Hospital of Chicago · Chicago, IL · Get directions →

    This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.

    ✓ Study care freePhase 2Ages 16–20Learn more →
  • DepressionParkinson's disease

    Imaging Depression in Parkinson's Disease

    Studying brain changes linked to depression in people with Parkinson’s

    📍 Yale University · New Haven, CT · Get directions →

    The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • High blood pressureCOPD (chronic lung disease)

    Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

    Testing tadalafil to see if it improves shortness of breath in COPD with high blood pressure in the

    📍 Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, CO · +4 more US sites · Get directions →

    The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function.

    ✓ Study care freePhase 2Ages 35–89Learn more →
  • Parkinson's disease

    Ketamine for Veterans With Parkinson's Disease

    Testing ketamine for depression in veterans with Parkinson’s disease

    📍 San Francisco VA Medical Center, San Francisco, CA · San Francisco, CA · Get directions →

    Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

    Tracking how brain scans change over time in people with early Parkinson’s

    📍 Institute for Neurodegenerative Disorders · New Haven, CT · +1 more US site · Get directions →

    The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • DepressionParkinson's disease

    Psilocybin Therapy for Depression in Parkinson's Disease

    Testing whether psilocybin therapy improves depression symptoms in people with Parkinson’s disease

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Fatty liver disease (NASH/MASH)

    A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

    Testing efimosfermin in people with MASH-related compensated cirrhosis

    💵 May compensate

    📍 GSK Investigational Site · Chandler, AZ · +29 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • COPD (chronic lung disease)

    Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)

    Testing an add-on treatment for adults having a COPD flare with type 2 inflammation

    📍 University of Alabama at Birmingham Lung Health Center · Birmingham, AL · +21 more US sites · Get directions →

    This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

    Testing the safety and effect of a gene therapy put into the brain for moderate Parkinson’s disease

    📍 Mayo Clinic · Phoenix, AZ · +33 more US sites · Get directions →

    The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

    ✓ Study care freePhase 2Ages 45–75Learn more →
  • Parkinson's disease

    Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

    Testing an oral low-dose carbon monoxide liquid in people with Parkinson’s

    📍 Quest Research Institute · Farmington Hills, MI · Get directions →

    A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Fatty liver disease (NASH/MASH)

    Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

    Testing a medicine at two doses for safety and effects on fats in people with high triglycerides and

    💵 May compensate

    📍 OrsoBio Research Site · Guadalajara, Jalisco · Get directions →

    This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and efficacy of 2 dose levels of TLC-2716 in subjects with hypertriglyceridemia and nonalcoholic fatty liver disease as assessed by changes in fasting triglycerides, liver steatosis by MRI, and other biomarkers.

    ✓ Study care freePhase 2Ages 18–70Learn more →
  • COPD (chronic lung disease)

    A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

    Testing different doses of two inhaled medicines for COPD symptoms

    📍 SEC Clinical Research, LLC · Dothan, AL · +39 more US sites · Get directions →

    This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Pyridostigmine for the Treatment of Constipation in Parkinson Disease

    Testing pyridostigmine as a treatment for constipation in Parkinson disease

    📍 University of Vermont Medical Center · Burlington, VT · Get directions →

    Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    Rehabilitation of Airway Protection in Parkinson's Disease

    Testing therapy to improve airway protection problems in Parkinson’s

    📍 Purdue University · West Lafayette, IN · +1 more US site · Get directions →

    Airway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address these critical deficits.

    ✓ Study care freePhase 2Ages 50–90Learn more →
  • COPD (chronic lung disease)

    A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

    Testing how a study medicine affects safety and symptoms in people with COPD

    📍 University of Alabama at Birmingham Lung Health Center · Birmingham, AL · +39 more US sites · Get directions →

    The purpose of this clinical trial is to learn about the effects and safety of the study medicine PF-07275315 for the potential treatment of COPD. COPD is a condition that makes it difficult to breathe, which negatively impacts the quality of life and functioning of people who are affected.

    ✓ Study care freePhase 2Ages 35–80Learn more →
  • Obesity / overweightHigh blood pressureCOPD (chronic lung disease)

    Feasibility of Semaglutide in Advanced Lung Disease

    Testing whether semaglutide can be given safely to people with advanced lung disease

    📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →

    The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • COPD (chronic lung disease)

    A Study to Evaluate Solrikitug in Participants With COPD (ZION)

    Testing solrikitug in people with COPD to check safety and effects

    📍 University of Alabama at Birmingham Hospital · Birmingham, AL · +39 more US sites · Get directions →

    A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).

    ✓ Study care freePhase 2Ages 40–75Learn more →
  • Parkinson's disease

    📍 Cornell University Weill Medical College · New York, NY · Get directions →

    This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

    ✓ Study care freePhase 1Ages 30–75Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    18F-mFBG Cardiac Uptake With Lewy Body Dementia

    Testing a heart imaging tracer to see how Lewy body dementia affects nerve signals

    📍 Houston Methodist Neurological Institute · Houston, TX · Get directions →

    This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation. Effectiveness of 18F-mFBG imaging of the heart will be judged in terms of the quantitative difference between results for subjects with Lewy body and non-Lewy body neurologic disease as compared to historical data for healthy control subjects.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    Tenapanor in Synucleinopathy-Related Constipation

    Testing tenapanor for constipation related to Parkinson’s disease

    📍 Cedar Valley Digestive Health Center · Waterloo, IA · Get directions →

    Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

    ✓ Study care freePhase 2Ages 50–89Learn more →
  • Parkinson's disease

    Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

    Testing how much brain tau buildup is in people with Parkinson’s using PET scans

    📍 Institute for Neurodegenerative Disorders / XingImaging, LLC · New Haven, CT · Get directions →

    The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.

    ✓ Study care freePhase 2Ages 45–85Learn more →
  • Parkinson's disease

    A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    Testing two doses of an add-on medicine to levodopa for Parkinson’s with motor fluctuations

    📍 University of Arkansas for Medical Sciences · Little Rock, AR · +24 more US sites · Get directions →

    This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.

    ✓ Study care freePhase 2Ages 30–80Learn more →
  • COPD (chronic lung disease)

    A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

    Testing the right dose of a long-acting medicine for moderate to severe COPD

    📍 WB Contracted Clinical Research Site · Miami Lakes, FL · +3 more US sites · Get directions →

    This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate - severe chronic obstructive pulmonary disease (COPD). WIN378 blocks the action of a protein called TSLP that causes inflammation in the lung and may contribute to COPD control and symptoms.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • High cholesterol

    A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

    Testing how safe and well weekly injections of alirocumab work for high cholesterol in adults

    📍 Anaheim Clinical Trials · Anaheim, CA · +29 more US sites · Get directions →

    This study is researching an experimental drug called alirocumab, referred to as "study drug". In the United States, alirocumab is approved for the treatment of hypercholesterolemia (high blood cholesterol levels).

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Fatty liver disease (NASH/MASH)

    Milk Thistle Clinical Trial in Pediatric NAFLD

    Testing milk thistle for children with fatty liver disease

    💵 May compensate

    📍 University Hospitals Cleveland Medical Center · Cleveland, OH · Get directions →

    Pediatric Fatty Liver disease is a growing problem in the United States and is expected to be the leading cause of Liver Transplantation in Adults in 20 years. Following lifestyle changes such as diet restrictions and exercise may be difficult to consistently maintain.

    ✓ Study care freePhase 2Ages 9–22Learn more →
  • Fatty liver disease (NASH/MASH)

    Digoxin In NASH (CODIN)

    Testing digoxin for people with metabolic fatty liver inflammation

    📍 Yale New Haven Health · New Haven, CT · +1 more US site · Get directions →

    Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was recently renamed metabolic associated steatohepatitis (MASH), involves lifestyle interventions to promote weight loss and to treat comorbidities such as hypertension, hyperlipidemia, and diabetes mellitus.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Parkinson's disease

    rTMS to Improve Cognition in Parkinson's

    Testing whether noninvasive brain stimulation can improve thinking in people with Parkinson’s

    📍 Jesse Brown VA Medical Center, Chicago, IL · Chicago, IL · +1 more US site · Get directions →

    The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease or atypical parkinsonism and mild impairments in their thinking. The hypothesis is that rTMS can improve thinking for people with Parkinson's disease or atypical parkinsonism who are experiencing mild problems with their thinking ability.

    ✓ Study care freePhase 1Ages 50+Learn more →
  • Parkinson's disease

    Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

    Testing a wearable sensor that gives feedback for swallowing therapy in Parkinson’s

    📍 Purdue University · West Lafayette, IN · Get directions →

    Dysphagia, or difficulty swallowing, is a common symptom of many neurological diseases but its treatment is not well established or easily accessible. To start addressing this gap, the researchers developed and validated a cost-effective wearable surface electromyography (sEMG) biofeedback sensor technology (i-Phagia), optimized to record muscle activity from the head/neck and provide biofeedback to patients and adherence data to clinicians during swallow therapy.

    ✓ Study care freePhase 2Ages 50–90Learn more →
  • Parkinson's disease

    Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

    Testing varenicline to reduce falls and improve walking multitasking in Parkinson’s

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo.

    ✓ Study care freePhase 2Ages 45+Learn more →
  • COPD (chronic lung disease)

    The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)

    Studying how sleep apnea together with COPD affects heart health

    📍 UCSD Sleep Research · La Jolla, CA · Get directions →

    Major progress has been made in the area of cardiovascular disease, but we believe that further progress will involve mechanistically addressing underlying respiratory causes including chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). The most common cause of death in COPD is cardiovascular, although mechanisms are unknown.

    ✓ Study care freePhase 2Ages 40–79Learn more →
  • Dementia / Alzheimer'sParkinson's diseaseMultiple sclerosis (MS)

    Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

    Testing safety of a PET imaging tracer in people with ALS, AD, MS, PD

    📍 UCSF · San Francisco, CA · +2 more US sites · Get directions →

    This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Parkinson's disease

    A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease

    Testing the safety and side effects of DSP-1083 implanted in people with Parkinson’s disease

    📍 University of Kentucky Medical Center · Lexington, KY · +1 more US site · Get directions →

    The Goal of this study is to evaluate the safety, tolerability, and clinical responses following implantation of DSP-1083. Study enrolls both male and female patients in 2 cohorts.

    ✓ Study care freePhase 1Ages 40–72Learn more →
  • Fatty liver disease (NASH/MASH)

    Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH

    Testing resmetirom in people with MASH-related liver scarring after liver transplant

    💵 May compensate

    📍 University of California San Diego · La Jolla, CA · +15 more US sites · Get directions →

    A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • High cholesterolLupus (SLE)

    IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy

    Testing certolizumab added to usual treatment to improve pregnancy in lupus and antiphospholipid

    📍 Hospital for Special Surgery · New York, NY · +1 more US site · Get directions →

    This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and repeatedly positive tests for lupus anticoagulant (LAC) to determine if this regimen will improve pregnancy outcomes. All enrolled patients will receive certolizumab, and pregnancy outcomes will be compared to those of women with APS and repeatedly positive tests for LAC enrolled in a previous study by the investigators.

    ✓ Study care freePhase 2Ages 18–40WomenLearn more →
  • COPD (chronic lung disease)

    Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy

    Comparing a lung scan that uses xenon MRI with a radioactive scan for COPD

    📍 University of Virginia Health System · Charlottesville, VA · Get directions →

    Hyper polarized Xenon-129 MRI will be directly compared to a radioactive Xe-133 scintigraphy to detect defects in lung ventilation from airflow limitation. This study is conducted as a pilot study with intention to conduct a larger clinical trial.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Parkinson's disease

    The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

    Testing brain inflammation in people with Parkinson’s using PET scans

    📍 UAB Advanced Imaging Facility · Birmingham, AL · Get directions →

    The primary objective of this substudy is to measure the concentration and the regional brain distribution of activated brain microglia/macrophages using the PET ligand \[18F\]DPA-714 in participants enrolled in the UAB Innate and Adaptive Immunity in Parkinson's Disease (Clinical Research Core) and Longitudinal \[18F\]DPA-714 Imaging in a Parkinson Disease Cohort studies. The PET tracer \[18F\]DPA-714 binds to the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor) in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of neuroinflammation.

    ✓ Study care freePhase 1Ages 30+Learn more →
  • COPD (chronic lung disease)

    Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

    Testing whether lung transplant first can improve lung function before bone marrow transplant for

    📍 UPMC Presbyterian · Pittsburgh, PA · +1 more US site · Get directions →

    The purpose of this study is to determine whether a lung transplantation prior to bone marrow transplantation (BMT) would allow for restoration of pulmonary function prior to BMT, allowing to proceed to BMT, to restore hematologic function.

    ✓ Study care freePhase 1Ages 18–60Learn more →
  • Type 2 diabetesFatty liver disease (NASH/MASH)

    Low-Dose Pioglitazone in Patients With NASH (AIM 2)

    Testing a low-dose diabetes medicine to see effects on liver changes in NASH

    💵 May compensate

    📍 University of Florida · Gainesville, FL · Get directions →

    To determine the safety and efficacy of low-dose pioglitazone (15 mg per day) on liver histology in in patients with T2DM with biopsy-proven nonalcoholic steatohepatitis (NASH).

    ✓ Study care freePhase 2Ages 21–75Learn more →
  • High blood pressureCOPD (chronic lung disease)

    Pulmonary Hypertension SOLAR

    Testing a noninvasive MRI pattern to study lung blood vessel changes in pulmonary hypertension

    📍 Duke University Medical Center · Durham, NC · Get directions →

    The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • COPD (chronic lung disease)

    Oral Sildenafil for Exercise Capacity, Dyspnea and Cardiopulmonary Function in COPD

    Testing sildenafil taken by mouth to improve exercise ability and breathing in people with COPD

    📍 Clinical Physiology Laboratory · Edmonton, Alberta · Get directions →

    Chronic obstructive pulmonary disease (COPD) is a condition characterized by airway obstruction. Patients with COPD experience significant shortness of breath on exertion.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease

    Testing nasal insulin and glutathione added to usual care in people with Parkinson’s

    📍 Institute for Neuroimmune Medicine · Davie, FL · +2 more US sites · Get directions →

    This study will be evaluating the safety and efficacy of insulin and glutathione in subjects with Parkinson's Disease compared to placebo.

    ✓ Study care freePhase 2Ages 30+Learn more →
  • COPD (chronic lung disease)

    Effect of Ensifentrine on Sputum Markers of Inflammation in COPD

    Testing whether nebulized ensifentrine changes lung inflammation markers in people with COPD

    📍 University of Alabama at Birmingham · Birmingham, AL · +2 more US sites · Get directions →

    This is a randomized, double-blind, placebo-controlled, two-period cross-over study of nebulized ensifentrine (3 mg) or placebo administered BID for two 8-week Treatment Periods. All participants with receive both ensifentrine and placebo during participation.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Fatty liver disease (NASH/MASH)

    Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant

    Testing whether semaglutide can prevent weight gain after liver transplant

    📍 Virginia Commonwealth University · Richmond, VA · Get directions →

    In this study, semaglutide will be compared to placebo (a look-alike inactive substance, a "sugar pill") to determine if its use will prevent weight gain after liver transplantation (LT). In addition, researchers will be testing to determine if semaglutide prevents the development of Non-Alcoholic Fatty Liver Disease (NAFLD) after transplant through Magnetic Resonance Imaging (MRI) and laboratory results.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Soluble Fibre Supplementation in NAFLD

    Testing a fiber supplement to see how it affects liver fat in children with non-alcoholic fatty

    📍 McMaster University Medical Center · Hamilton, Ontario · Get directions →

    The FIND study will look at the effect of a nutritional mixed fibre supplement, oligofructose and inulin (OF+INU), on children with non-alcoholic fatty liver disease. In this randomized, double- blind controlled trial, subjects will be given a supplement, in the form of oral pills, and will have bloodwork performed, their diets analyzed, and liver fat measured at several timepoints.

    ✓ Study care freePhase 2Ages 8–17Learn more →
  • Fatty liver disease (NASH/MASH)

    📍 Arizona Liver Health · Chandler, AZ · +39 more US sites · Get directions →

    This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH).

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • Fatty liver disease (NASH/MASH)

    Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

    Testing thyroid hormone to treat advanced fatty liver disease in veterans

    📍 Harry S. Truman Memorial, Columbia, MO · Columbia, MO · Get directions →

    Nonalcoholic steatohepatitis (NASH) is the aggressive form of nonalcoholic fatty liver disease, which is rapidly becoming a worldwide public health problem. It is more common in the military and Veteran population compared to the general US population.

    ✓ Study care freePhase 2Ages 18–75Learn more →
  • DepressionParkinson's disease

    Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease

    Testing whether a 12-week multi-strain probiotic can treat depression in people with Parkinson’s

    📍 Pacific Parkinson's Research Centre · Vancouver, British Columbia · Get directions →

    This study evaluates the use of an oral multi-strain probiotic in the treatment of depression in individuals with Parkinson's Disease. Participants will be randomized to either a 12-week multi-strain probiotic treatment or placebo intervention.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

    Testing BHV-8000 for safety and effectiveness in adults with early Parkinson's disease

    📍 Site-049 · Birmingham, AL · +14 more US sites · Get directions →

    A study to determine if BHV-8000 is efficacious, safe and tolerable in adults diagnosed with early Parkinson's disease.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Showing the first 60 of 62. Add filters or a location to narrow down.